Open sstemann opened 2 years ago
Not sure why aragorn never came back last night, but I just ran this (async) via the ars and got back results: https://arax.ncats.io/?r=b05e5766-3efe-4af9-9423-771671471f65
The first few results are doxorubicin, but all of the chemicals listed above with the exception of eribulan all occur in the knowledge graph somewhere.
Also, we dug into the logs a bit; it looks like it ran fine last night, but timed out when posting back to the ARS. Currently, there's a timeout (on our side) set to 120s for that post, but we're going to make it a bit longer.
Query: C.2_Doxorubicin_liposarcoma.json Async PK: 604132c0-b073-49ad-be84-902231915061 Sync PK: c9a3d438-c2c8-4900-9535-e5393d51c888 Control: https://pubmed.ncbi.nlm.nih.gov/?term=liposarcoma+chemotherapy&filter=pubt.review result #3: https://pubmed.ncbi.nlm.nih.gov/32026050/
Historically, systemic therapy options have been limited to cytotoxic chemotherapy agents, including doxorubicin, ifosfamide, gemcitabine, and docetaxel
recently, however, there have been phase II and III trials establishing clinical benefit of the cytotoxic agents trabectedin and eribulin along with the tyrosine kinase inhibitor pazopanib in patients with advanced liposarcoma and DDLPS
[Pending ARAX Results Tracking Sheet]
*async results![image](https://user-images.githubusercontent.com/38321826/139459309-9ed36f84-2404-43bf-8a14-a060b21c47ca.png)
sync results![image](https://user-images.githubusercontent.com/38321826/139458618-516897c5-889c-42ec-ba12-e504f76f9a6d.png)